Aarti Pharmalabs - Public Comps and Valuation Multiples

Aarti Pharmalabs Overview

About Aarti Pharmalabs

Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.

Founded

2019

HQ

Employees

2.2K+

Website

aartipharmalabs.com

Sectors

Contract Research & Manufacturing
Nutraceuticals & Cosmeceuticals
BioTech

Financials

Last FY Revenue $235M

Last FY EBITDA $53.5M

EV

$892M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Aarti Pharmalabs Financials

See Aarti Pharmalabs valuation multiples based on analyst estimates

Aarti Pharmalabs P&L

In the most recent fiscal year, Aarti Pharmalabs reported revenue of $235M and EBITDA of $53.5M.

Aarti Pharmalabs expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Aarti Pharmalabs valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$235M	XXX	XXX	XXX
Gross Profit	XXX	$97.8M	XXX	XXX	XXX
Gross Margin	XXX	42%	XXX	XXX	XXX
EBITDA	XXX	$53.5M	XXX	XXX	XXX
EBITDA Margin	XXX	23%	XXX	XXX	XXX
EBIT	XXX	$42.6M	XXX	XXX	XXX
EBIT Margin	XXX	18%	XXX	XXX	XXX
Net Profit	XXX	$30.7M	XXX	XXX	XXX
Net Margin	XXX	13%	XXX	XXX	XXX
Net Debt	XXX	$44.8M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Aarti Pharmalabs including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Aarti Pharmalabs achieved $235M in revenue and $53.5M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$235M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$97.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	41.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$53.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	22.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$42.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	18.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$30.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	13.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$44.8M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Aarti Pharmalabs

This financial data table provides comprehensive performance metrics for Aarti Pharmalabs, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Aarti Pharmalabs reported $235M in total revenue.
Fiscal year EBITDA was $53.5M.
The company maintained a gross profit margin of 41.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 22.7%.
Net profit margin reached 13.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Aarti Pharmalabs. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Aarti Pharmalabs Stock Performance

Aarti Pharmalabs has current market cap of INR 75.5B (or $851M), and EV of INR 79.1B (or $892M).

Market Cap Evolution

Aarti Pharmalabs Stock Data

As of October 17, 2025, Aarti Pharmalabs's stock price is INR 832 (or $9).

See Aarti Pharmalabs trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$892M	$851M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Aarti Pharmalabs Valuation Multiples

Aarti Pharmalabs's trades at 3.9x EV/Revenue multiple, and 17.4x EV/EBITDA.

See valuation multiples for Aarti Pharmalabs and 15K+ public comps

Aarti Pharmalabs Financial Valuation Multiples

As of October 17, 2025, Aarti Pharmalabs has market cap of $851M and EV of $892M.

Equity research analysts estimate Aarti Pharmalabs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Aarti Pharmalabs's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$851M	XXX	$851M	XXX	XXX	XXX
EV (current)	$892M	XXX	$892M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	3.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	17.4x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	21.9x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	29.2x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-99.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Aarti Pharmalabs Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Aarti Pharmalabs Margins & Growth Rates

Aarti Pharmalabs's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $26K for the same period.

Aarti Pharmalabs's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Aarti Pharmalabs's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Aarti Pharmalabs and other 15K+ public comps

Aarti Pharmalabs Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	22%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$26K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	2%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	23%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial